EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer

Samuel P G Rollin, Mitchell G Lawrence, Anthony M Joshua, Luke A Selth iD

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-24-0208 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Samuel P G Rollin und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Androgens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 220 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibiting the activity of the androgen receptor (AR) is the cornerstone treatment for advanced prostate cancer. AR-targeted therapies are highly effective in slowing disease progression but are not curative. Failure of these therapies results in a disease state termed castration-resistant prostate cancer, which is associated with significant patient morbidity and mortality. In most cases, resistance to AR-targeted therapies arises due to alterations that reactivate the AR signalling axis. Interestingly, it has long been recognised that potent activation of AR with supraphysiological levels of androgens can suppress prostate cancer growth in both preclinical models and patients. This intriguing paradox, where both inhibition and activation of AR have anti-cancer effects, is now being harnessed clinically in the form of bipolar androgen therapy (BAT). This review describes mechanisms underlying the tumour-suppressive functions of AR in the context of potent androgenic stimulation and discusses how our maturing understanding of these processes is influencing the clinical deployment of BAT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, AndrogenProstatic NeoplasmsAndrogensHumansMaleAnimalsProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsAndrogen AntagonistsSignal TransductionAntineoplastic Agents, Hormonal

Stichwörter der Autor:innen

androgen receptorbipolar androgen therapyprostate cancertestosterone

Substanzen

Receptors, AndrogenAndrogensAndrogen Receptor AntagonistsAR protein, humanAndrogen AntagonistsAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

ORCID-Profile: Luke A Selth

Zitieren

APA

Rollin, S. P. G., Lawrence, M. G., Joshua, A. M., & Selth, L. A. (2025). Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0208

Vancouver

Rollin SPG, Lawrence MG, Joshua AM, Selth LA. Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0208

BibTeX
@article{Rollin2025,
  author = {Rollin, Samuel P G and Lawrence, Mitchell G and Joshua, Anthony M and Selth, Luke A},
  title = {Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-24-0208}
}
Kostenlos starten →